Nevirapine(neh veer’ ah pine)
Viramune, Viramune XRDNC
PREGNANCY CATEGORY B
Drug Classes
Antiviral
Non-nucleoside reverse transcriptase inhibitor
Therapeutic Actions
Antiretroviral activity; binds directly to HIV-1 reverse transcriptase and blocks the replication of HIV by changing the structure of the HIV enzyme.
Indications
Treatment of HIV-1 infection in combination with other antiretroviral drugs
Contraindications and Cautions
Contraindicated with allergy to nevirapine; lactation; moderate to severe hepatic impairment.
Use cautiously with renal or hepatic impairment, rash, pregnancy.
Available Forms
Tablets—200 mg; ER tabletsDNC—400 mg; oral suspension—50 mg/5 mL
Dosages
Adults
200 mg PO daily for 14 days; if no rash appears, then 200 mg PO bid, or 400 mg ER tablet PO once daily with other antivirals. Daily dose should not exceed 400 mg/day. If dosing is interupted for more than 7 days, restart with 14-day immediate-release tablet regimen and if no rash occurs, ER tablet may be used for once-a-day dosing.
Pediatric patients 15 days and older
150 mg/m2 PO once daily for 14 days, then 150 mg/m2 PO bid; maximum dose, 400 mg/day.
Pharmacokinetics
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
